Clinical trials: Cognitive Impairment
Schizophrenia
Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia
The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with stable schizophrenia who are being treated with an atypical antipsychotic and who are active cigarette smokers, to assess the safety and…
- Trial name
- HALO (NCT00528905)
- Testing
- AZD3480
- Where
- 80 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Cognition Disorder, Nervous System Diseases
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
The purpose of this follow-up study is to assess the long-term safety and tolerability of galantamine in individuals with mild cognitive impairment who participated in a previous study with galantamine
- Conditions
- Cognition Disorder, Nervous System Diseases, Mental Disorders, Brain Diseases
- Trial name
- NCT00240695
- Testing
- galantamine hydrobromide
- Volunteers
- 724 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Menopause, Perimenopausal Disorder
Virtual perI-/Menopause Registry of AusTrALia
13 million (50.7%) Australians are born with ovaries, 14% (~3 million) are currently aged 40-59 yrs, \& all such who live to midlife will experience menopause, defined as >12 months without a period.
- Conditions
- Menopause, Perimenopausal Disorder, Postmenopausal Symptoms, Health Knowledge, Attitudes, Practice
- Trial name
- VITAL (NCT06487130)
- Testing
- N/A Observational Registry
- Where
- Australia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Bespoke Clinical Research
Heart Failure, Cognitive Impairment
HeartMapp: Assessment and Treatment for Heart Failure
In the current application, the investigators propose to elaborate upon, reconstruct and advance to pivotal trial readiness a recently validated mobile application (HeartMapp), designed for the ecological momentary assessment and…
- Trial name
- HeartMapp (NCT03827954)
- Testing
- HeartMapp+CT
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Posit Science Corporation
Alzheimer's Disease
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of two fixed doses (16mg/day and 24mg/day) of galantamine (a drug for treating dementia) versus placebo for the treatment of patients with Alzheimer's disease.
- Trial name
- NCT00814801
- Testing
- Galantamine 16 mg/day, Galantamine 24 mg/day
- Where
- Japan
- Volunteers
- 580 people
- Sponsor
- Janssen Pharmaceutical K.K.
Cognitive Impairment, End Stage Renal Disease
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
This study will evaluate the tolerability, feasibility, and efficacy of the AKST1210 column in subjects with end-stage renal disease with cognitive impairment (ESRD-CI) undergoing hemodialysis 3 times per week.
- Trial name
- NCT04527328
- Testing
- AKST1210, Hemodialysis
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alkahest, Inc.
Breast Cancer, Cognitive Symptoms
Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment
The investigators hypothesize that continuous active interaction with environments that are demanding to sensory, cognitive, and motor systems, together with imbedded rewards for successful performance, will help improve memory…
- Conditions
- Breast Cancer, Cognitive Symptoms, Memory Disorders
- Trial name
- NCT00387062
- Testing
- Computer-based Cognitive Training
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Posit Science Corporation
Healthy Aging, Alzheimer's Disease
The Feasibility, Safety and Tolerability of VR-based Audiovisual Stimulation
This single-session, within-subject, sham-controlled early feasibility study evaluated the safety, tolerability, and feasibility of delivering 40 Hz audiovisual (gamma sensory) stimulation through a virtual reality (VR) headset…
- Conditions
- Healthy Aging, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- CFS (NCT06234930)
- Testing
- Audiovisual stimulation VR system
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Clarity Health Technologies, Inc
Primary Biliary Cholangitis (PBC)
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
The present phase 1b/2 randomised, double-blind, placebo-controlled, two-part study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of two dose levels of golexanolone…
- Trial name
- NCT07304843
- Testing
- golexanolone
- Where
- 38 sites in Germany, Greece and 6 more
- Volunteers
- 207 people
- Sponsor
- Umecrine Cognition AB
Down Syndrome, Cognitive Dysfunction
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10
The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of cognitive dysfunction shown by children with Down syndrome, aged 6 to 10 years.
- Trial name
- NCT00754013
- Testing
- Aricept (Donepezil hydrochloride)
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Eisai Inc.
Down Syndrome, Cognitive Dysfunction
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17
The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of the cognitive dysfunction shown by children with Down syndrome, aged 11 to 17.
- Trial name
- NCT00754052
- Testing
- Aricept (donepezil hydrochloride)
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Eisai Inc.
Stroke
Evaluating Neuroprotection in Aneurysm Coiling Therapy
This is a randomized, double-blind, placebo-controlled, single-dose, design investigating the safety, tolerability and efficacy of NA-1, a peptide designed to reduce ischemic brain damage.
- Trial name
- ENACT (NCT00728182)
- Testing
- NA-1
- Where
- 14 sites in United States, Canada
- Volunteers
- 185 people
- Sponsor
- NoNO Inc.
Alzheimer Disease, Cognition Disorders
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease…
- Trial name
- NCT00000174
- Testing
- Rivastigmine
- Where
- 15 sites in United States
- Sponsor
- Novartis
Down Syndrome
A Study of ACI-24 in Adults With Down Syndrome
This study is a prospective multicenter, placebo-controlled, double-blind, randomized study to assess the effect of one dose ACI-24 versus placebo over a 74-week treatment period and 26-week safety follow-up period.
- Trial name
- NCT04373616
- Testing
- ACI-24
- Sponsor
- AC Immune SA
Memory Loss
The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)
To investigate the efficacy and safety of donepezil in individuals with mild cognitive impairment on measures of cognition, global function and behavior.
- Trial name
- NCT00293176
- Testing
- Donepezil Hydrochloride
- Where
- 54 sites in United States
- Volunteers
- 821 people
- Sponsor
- Eisai Inc.
Major Depressive Disorder, MDD
Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
Xanamem is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
- Conditions
- Major Depressive Disorder, MDD, Cognitive Impairment
- Trial name
- NCT05657691
- Testing
- Xanamem™
- Where
- 12 sites in Australia, United Kingdom
- Volunteers
- 167 people
- Sponsor
- Actinogen Medical
Healthy, Alzheimer's Disease
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who are healthy, those who have mild cognitive impairment due to Alzheimer's…
- Conditions
- Healthy, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- NCT02614131
- Testing
- LY2599666, Solanezumab
- Where
- 5 sites in United States, Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease, Cognitive Impairment
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease
This study is a multicenter, double blind, randomized, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of different doses, regimens and combinations of Tau targeted vaccines in participants with…
- Conditions
- Alzheimer's Disease, Cognitive Impairment, Tauopathies, Mild Cognitive Impairment
- Trial name
- NCT04445831
- Testing
- ACI-35.030, JACI-35.054
- Where
- 9 sites in Finland, Netherlands and 2 more
- Volunteers
- 57 people
- Sponsor
- AC Immune SA
Schizophrenia, Impaired Cognition
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
- Trial name
- NCT01714661
- Testing
- EVP-6124
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 753 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer Disease, Dementia
Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's Disease, or Related Dementias
This study will evaluate Jigsawdio, a personalized multisensory jigsaw puzzle platform, for adults aged 60 years and older with mild cognitive impairment or mild dementia.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment
- Trial name
- NCT07839286
- Testing
- Jigsawdio Multisensory Puzzle Platform, Standard Jigsaw Puzzle Activity
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Callahan-Young LLC DBA Jigsawdio